Caplyta Doubles Depression Relief for Anxious Patients in New Subgroup Analysis

0 points · first seen 16h ago · 1 outlet · 0 comments

Caplyta MDD subgroup analysis in the Journal of Clinical Psychiatry finds lumateperone's effect size nearly doubles in major depressive disorder patients with the DSM-5 anxious distress specifier, rising from 0.44 to 0.85 on the MADRS. The 481-patient Study 501 post-hoc analysis finds a response NNT of three in this subgroup, representing about 43% of all MDD patients. — Tech Times

save

· share to X · Bluesky · copy link